Metastatic renal cell carcinoma is unresponsive to most chemotherapeutic agents employed to date including alkylating agents, antimetabolites, antibiotics, vinca alkaloids, and nitrosoureas. Progesterone derivatives or androgens give a low number of partial remissions and approximately a 20% subjective response rate. The current phase II study was undertaken to evaluate the therapeutic efficacy of a new investigational agent, 4' (9-acridinylamino)methanesulfon-m-anisidide (AMSA) in this disease.
|Original language||English (US)|
|Number of pages||2|
|Journal||Cancer treatment reports|
|State||Published - 1980|
All Science Journal Classification (ASJC) codes
- Cancer Research